Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis
Kidney Diseases · 18.06.2026 · 12 (1) · 693-710
DOI: 10.1159/000553106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Kidney Diseases, online erschienen am 18.06.2026. Verfasst von Lan Anh Thi Ke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Kidney disease is a major global health burden with limited regenerative treatment options. Induced pluripotent stem cells (iPSCs) offer patient-specific pluripotency and the potential to generate renal cells and organoids, making them a promising approach for kidney repair.
Methods
A systematic literature search was conducted in PubMed, ScienceDirect, Web of Science, and Cochrane Library for peer-reviewed studies investigating the therapeutic application of iPSCs in kidney disease up to February 2026. Risk of bias was assessed using the SYRCLE tool. Random effects meta-analyses were performed, and subgroup and meta-regression analyses were conducted to explore potential sources of heterogeneity.
Result
In this search, 23 preclinical studies encompassing 372 animals met the inclusion criteria, and no eligible human trials were identified. iPSC-based therapy was associated with reduced mortality (OR = 0.17; 95% CI: 0.05–0.52; p = 0.002) and improvements in blood urea nitrogen, serum creatinine, and histological injury scores. Subgroup and meta-regression analyses suggested that therapeutic response was influenced by biological factors, including cell type, disease model, delivery route, and treatment conditions. Notably, stronger effects were observed in acute kidney injury models and with direct iPSC-based interventions. However, substantial heterogeneity was observed across most renal outcomes (I2 > 90%), indicating considerable variability among studies. Conclusion: iPSC-based therapy demonstrates beneficial effects in experimental kidney disease, particularly in acute models. However, the high degree of heterogeneity, potential risk of bias, and limited safety data constrain the reliability and generalizability of these findings. Further optimization of therapeutic strategies and rigorous long-term safety evaluations are required to support clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Faculty of Medicine, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
- Department of Molecular Biology and Biochemistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Dental School, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
- Department of Pediatrics, Faculty of Medicine, Hai Phong University of Medicine and Pharmacy, Hai Phong, Vietnam.
- Faculty of Medicine, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
Zitieren
APA
Ke, L. A. T., Nguyen, A. N., Pham, N. M., Dang, L. P., Tran, H. Y. T., & Vo, Q. D. (2026). Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Diseases, 12(1), 693-710. https://doi.org/10.1159/000553106
Vancouver
Ke LAT, Nguyen AN, Pham NM, Dang LP, Tran HYT, Vo QD. Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis. Kidney Diseases. 2026;12(1):693-710. doi:10.1159/000553106
BibTeX
@article{Ke2026,
author = {Ke, Lan Anh Thi and Nguyen, Anh Ngoc and Pham, Nguyet Minh and Dang, Linh Phuong and Tran, Hai Yen Thi and Vo, Quan Duy},
title = {Therapeutic Applications of Induced Pluripotent Stem Cell Technology in Kidney Disease: A Systematic Review and Meta-Analysis},
journal = {Kidney Diseases},
year = {2026},
volume = {12},
number = {1},
pages = {693--710},
doi = {10.1159/000553106}
}
EUVIMED